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Abstract
Objectives To evaluate accuracy and inter-observer variability using Vesical Imaging-Reporting and Data System (VI-RADS)
for discrimination between non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC).
Methods Between September 2017 and July 2018, 78 patients referred for suspected bladder cancer underwent
multiparametric MRI of the bladder (mpMRI) prior to transurethral resection of bladder tumor (TURBT). All mpMRI
were reviewed by two radiologists, who scored each lesion according to VI-RADS. Sensitivity, specificity, positive
predictive value (PPV), and negative predictive value (NPV) were calculated for each VI-RADS cutoff. Receiver operating
characteristics curves were used to evaluate the performance of mpMRI. The Ƙ statistics was used to estimate inter-reader
agreement.
Results Seventy-five patients were included in the final analysis, 53 with NMIBC and 22 with MIBC. Sensitivity and specificity
were 91% and 89% for reader 1 and 82% and 85% for reader 2 respectively when the cutoff VI-RADS > 2 was used to define
MIBC. At the same cutoff, PPVand NPV were 77% and 96% for reader 1 and 69% and 92% for reader 2. When the cutoff VI-
RADS > 3 was used, sensitivity and specificity were 82% and 94% for reader 1 and 77% and 89% for reader 2. Corresponding
PPVand NPVwere 86% and 93% for reader 1 and 74% and 91% for reader 2. Area under curve was 0.926 and 0.873 for reader 1
and 2 respectively. Inter-reader agreement was good for the overall score (Ƙ = 0.731).
Conclusions VI-RADS is accurate in differentiating MIBC from NMIBC. Inter-reader agreement is overall good.
Key Points
• Traditionally, the local staging of bladder cancer relies on transurethral resection of bladder tumor.
•However, transurethral resection of bladder tumor carries a significant risk of understaging a cancer; therefore, more accurate,
faster, and non-invasive staging techniques are needed to improve outcomes.
•Multiparametric MRI has proved to be the best imaging modality for local staging; therefore, its use in suitable patients has the
potential to expedite radical treatment when necessary and non-invasive diagnosis in patients with poor fitness.
Keywords Urinary bladder neoplasms . Magnetic resonance imaging . Neoplasm grading . Diffusion magnetic resonance
imaging . Neoplasm staging
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ADC Apparent diffusion coefficient
AUC Area under curve
BCa Bladder cancer
DCE-MRI Dynamic contrast-enhanced MRI
DWI Diffusion-weighted imaging
MIBC Muscle-invasive bladder cancer
mpMRI Multiparametric MRI of the prostate
NMIBC Non-muscle-invasive bladder cancer
ROC Receiver operating characteristics
TURBT Transurethral resection of bladder tumor
VI-RADS Vesical Imaging-Reporting and Data System
Introduction
Bladder cancer (BCa) is the ninth most common malignancy
worldwide, with more than 80,000 cases diagnosed and
17,000 deaths in the USA each year [1, 2]. In Europe, approx-
imately 118,000 cases and 52,000 deaths were estimated in
2012 [3]. The majority of BCa are histologically typed as
urothelial carcinoma and stratified into low- and high-grade
cancers. High-grade lesions may be non-muscle-invasive
(NMIBC) and muscle-invasive (MIBC) cancers [4], with dis-
tinct treatments and clinical outcomes [5, 6].
The local staging of BCa traditionally relies on transure-
thral resection of bladder tumor (TURBT), with cross section-
al imaging (such as CT and MRI of abdomen, pelvis, and
thorax) used to assess nodal disease and distant metastases.
TURBT carries a significant risk of understaging a cancer
[7, 8], risks bladder perforation, can be a morbid uncomfort-
able procedure, and delays radical treatment in those whom it
is needed. Therefore, more accurate, faster, and non-invasive
staging techniques are needed to improve the outcomes from
BCa. Given its superior contrast resolution and the addition of
functional sequences, MRI has proved to be the best imaging
modality for local staging [9]. Several studies have tested its
ability to differentiate NMIBC from MIBC and two recent
meta-analysis have shown a pooled sensitivity of 87% and
92% and a specificity of 79% and 87%, respectively [10, 11].
As such, one could imagine replacing TURBTwith mpMRI in
suitable patients, with the potential for faster radical treatment
when necessary and non-invasive diagnosis and staging in
those with poor fitness. Indeed, an ongoing trial is currently
testing this hypothesis: ISRCTN Reference 35296862.
Despite the growing use of MRI in local staging of BCa,
there is a lack of standardization in terms of protocol,
reporting, and aims of imaging. A panel of experts has recent-
ly issued a reporting system aimed at standardizing
multiparametric MRI (mMRI) of the bladder for research
and clinical application, the Vesical Imaging-Reporting and
Data system (VI-RADS), in accordance with previously suc-
cessful attempts at standardizing mpMRI protocols [12, 13].
Particularly, the purpose of the 5-point scoring system pro-
posed is to define the risk of muscle invasion in untreated
patients with BCa. To date, however, the recently developed
score has not been validated in clinical practice.
Here we evaluate both the accuracy and inter-observer var-
iability with the use of VI-RADS for discrimination between




This retrospective study received Institutional Review Board
prior to starting and the need for informed consent was
waived.
Table 1 Multiparametric MRI
protocol at 3 T. Source: [12] T2W DWI DCE MRI
Parameter setting at 3.0 T 4690 2500 up to 5300 3.8
TR (ms) 119 61 1.2
TE (ms) 119 61 15
Flip angle (degree) 90 90 15
FOV (cm) 23 32 27
Matrix 400 × 256–320 128 × 128 192 × 192
Slice thickness (mm) 3–4 3–4 1
Slice gap (mm) 0–0.4 0.3–0.4 0
Number of excitations 2–3 4–10 1
B values (s/mm2) 0–88–1000 up to 2000
Temporal resolution (s) 5
TR repetition time, TE echo time, FOV field of view
Eur Radiol
Fig. 1 Schematic representation
of VI-RADS scoring. Source:
[12]. SI: signal intensity, CE: dy-
namic contrast-
enhanced imaging, DWI: diffu-
sion-weighted imaging
Fig. 2 Sixty-seven-year-old man presenting with hematuria and a
bladder mass discovered at ultrasound. a T2W imaging shows an
exophytic lesion on the posterior bladder wall, > 1 cm in greatest
dimension, with a low SI stalk and preservation of the low SI
representing the muscularis propria. VI-RADS score for T2W im-
aging is 2. b and c DWI (b = 2000) and ADC map, respectively,
show an exophytic lesion with restricted diffusion, with low SI
stalk on DWI and muscularis propria with continuous intermediate
signal on DWI. VI-RADS score for DWI is 2. d DCE imaging
shows early enhancement of the lesion and inner layer, without
early enhancement of the muscularis propria. DCE was assigned a
VI-RADS category 2 . Overa l l VI-RADS score was 2.
Histopathology after TURBT and RE-TURBT confirmed a T1 tu-
mor. T2W T2-weighted, SI signal intensity, DWI diffusion-
weighted imaging, ADC apparent diffusion coefficient
Eur Radiol
Between September 2017 and July 2018, patients referred
to our institution for suspected BCa were offered an institu-
tional protocol which entailed mpMRI prior to TURBT.
Imaging protocol
All exams were performed using a 3 T magnet (Discovery
MR750W, GE Healthcare), equipped with a 32-channel
phased-array coil. The imaging protocol of the pelvis, focused
on the bladder, was VI-RADS-compliant and included 2D fast
spin-echo (FSE) or PROPELLER T2-weighted sequences in
axial, coronal and sagittal planes, axial diffusion-weighted
imaging (DWI), and axial dynamic contrast-enhanced imag-
ing (DCE) after a single injection of Gadovist administered at
a dose of 0.1 mmol/kg at a rate of 3 ml/s. Imaging protocol is
summarized in Table 1. Patients were administered intramus-
cular antispasmodic agent and instructed to start drinking
500–1000 ml of water in 30 min before the examination to
obtain an adequate distension of the bladder.
TURBT and histopathologic evaluation
All patients underwent bipolar TURBT within 6 weeks after
mpMRI at the Department of Gynecological-Obstetric and
Urological Sciences, BSapienza^ Rome University, and at
Department of Urology, Regina Elena National Cancer
Institute, Rome, Italy. All the procedures were carried out by
the same two experienced surgeons. According to the
European association of Urology (EAU) Guidelines [6],
high-risk NMIBC was defined as any high-grade transitional
cell carcinoma (TCC) (primary or recurrent), any multiple,
recurrent and large (> 3 cm) low-grade TCC, and any primary
carcinoma in situ (Cis). Four weeks after the first TURB, all
high-risk patients underwent re-TURBTwith resection of the
previous primary tumor site to eliminate any suspicious resid-
ual areas and to confirm the stage of the disease. All tumor
samples were analyzed by two uropathologists with more than
15 years of experience in BCa.
MR image interpretation
All mpMRI exams were reviewed by two radiologists with a
special interest in urogenital imaging, with more than 10 years
of experience (reader 1) and 5 years of experience (reader 2).
Both radiologists had read more than 50 mpMRI of the blad-
der in the years prior to the beginning of the study, starting
from 2014. Both readers were blinded to clinical history and
histopathology results and were asked to score each lesion, up
Fig. 3 Seventy-eight-year-old
man with hematuria. a T2W
imaging show a lesion > 1 cm in
the right lateral bladder wall, with
intermediate SI that extends
through the muscularis propria.
T2W imaging was assigned a VI-
RADS category 4. b and c DWI
(b = 2000) and ADCmaps show a
lesion with significant restricted
diffusion, extending through the
muscularis propria. VI-RADS
score of DWI was 4. d DCE im-
aging shows early and heteroge-
neous enhancement of the lesion,
which extends through the
muscularis propria. DCE was
assigned a VI-RADS category 4.
Overall VI-RADS score was 4.
Pathologic stage after cystectomy
was pT2bN0Mx. T2W T2-





to 3 per patient, according to VI-RADS, which is summarized
in Fig. 1. When patients presented more than one lesion, only
the lesion with the highest VI-RADS was considered. A sche-
matic representation of each VI-RADS category is depicted in
supplementary fig. 1. In brief, T2WI is the first modality to be
assessed, looking for a continuous low signal intensity (SI)
line in the bladder wall that represents an intact muscularis
propria. As for DWI (high b-value images), the tumor is hy-
perintense, with a corresponding hypointensity onADCmaps,
while the tumor stalk and inner layer have low SI. On DCE
images, the tumor and inner layer enhance early and can en-
hance to the same degree, while the muscularis propria should
maintain a low SI in the early phase. Case examples of VI-
RADS scoring are shown in Figs. 2 and 3. An example of
false-negative MRI exam is depicted in Fig. 4. An example
of false-positive MRI exam is shown in supplementary fig. 2.
Statistical analysis
Sensitivity, specificity, positive predictive value (PPV), and
negative predictive (NPV) value were calculated for both
readers, using a 2 × 2 contingency table, and for each VI-
RADS category used as cutoff. MIBC (stage pT2 or higher)
correctly classified by mpMRI was considered as true
positive. The performance of mpMRI with combined T2W,
DWI, and DCE and the use of VI-RADS was assessed by
means of receiver operating characteristics (ROC) curve anal-
ysis, for both readers. The Ƙ statistics was used to estimate
inter-reader agreement. The bootstrap resampling procedure
was used to calculate the standard error of the Ƙ estimates,
as previously described [14]. All statistical analysis was per-
formed by using software SPSS version 23.0 (IBMCorp.). All
tests were two-sided and statistical significance was set at
p < 0.05.
Results
Patient and lesion characteristics
In total, 94 patients were eligible for inclusion, of which 8
were excluded because of a cardiac pace-maker, 5 for claus-
trophobia, and 3 for renal failure. A total of 78 patients were
enrolled in the study, and underwent mpMRI (median 2, range
1–6 weeks) prior to TURBT. Of these, 2 were excluded be-
cause of incomplete mpMRI imaging and one patient because
the tumor identified at imaging was recurrent ureteric cancer.
The final study population included 75 patients (including 13
Fig. 4 Seventy-year-old man with history of T1 BCa treated with
TURBT. a T2W imaging shows a broad based tumor > 1 cm, localized
on the posterior wall of the bladder, with thickened inner layer and
uninterrupted low SI of the muscularis propria. VI-RADS score of
T2WI was 2. b, c DWI (b = 2000) and ADC map, respectively, show a
lesion with restricted diffusion, without a stalk, and a muscularis propria
with continuous intermediate signal, particularly evident on ADC
map.VI-RADS score of DWI was 2. d DCE imaging shows early en-
hancement of the lesion and the inner layer, without extension through the
muscularis propria. VI-RADS score of DCE was 2. Overall VI-RADS
score was 2. Histopathology after TURBT and RE-TURBT showed a T2
tumor; therefore, the case was recorded as false-negative. T2W T2-
weighted, SI signal intensity, DWI diffusion-weighted imaging, ADC
apparent diffusion coefficient
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females), with a median age of 69 years (Table 2). A total of
53 patients were diagnosed with NMIBC and 22 patients with
MIBC. Eighteen patients underwent radical cystectomy.
Table 3 summarizes the lesions characteristics, including
stage, size, and location.
VI-RADS performance, ROC curve analysis,
and inter-reader agreement
The proportion of patients assigned to each VI-RADS catego-
ry is summarized in Table 4. The sensitivity of VI-RADS for
reader 1 and 2 was 91% (95% CI 71–99) and 82% (95% CI
60–95), respectively, when the cutoff VI-RADS > 2 was used
to define MIBC. The specificity for the same cutoff was 89%
(95% CI 77–96) and 85% (95% CI 72–93) for reader 1 and 2
respectively. PPVand NPVat the same cutoff were 77% (95%
CI 56–91) and 96% (95% CI 86–99) for reader 1 and 69%
(95% CI 48–85) and 91% (95% CI 81–98) for reader 2. If the
cutoff to define MIBC was moved at VI-RADS > 3, sensibil-
ity and specificity were 82% (95% CI 60–95) and 94% (95%
CI 84–99) for reader 1; for reader 2, they were 77% (95% CI
55–92) and 89 (95% CI 77–96). PPV and NPV at the same
cutoff were 86% (95% CI 63–97) and 93% (95% CI 82–98)
for reader 1; for reader 2, they were 74% (95% CI 51–90) and
91% (95% CI 79–97). Accuracy was 91% for reader 1 at both
cutoffs; for reader 2, it was 84% for the first cutoff and 85%
for the second. Table 5 summarizes sensitivity and specificity
for both readers at each cutoff.
ROC curve analysis showed that the optimal criterion,
identified with the Youden’s index, was VI-RADS > 2, for
both readers. The area under curve (AUC)was similar for both
readers: 0.926 (95% CI 0.842 to 0.974) for reader 1 and 0.873
(95% CI 0.776 to 0.938) for reader 2, respectively (p = 0.21).
ROC curve analysis is summarized in Fig. 5.
Inter-reader agreement evaluated by the Ƙ statistics was
good for the overall VI-RADS score (Ƙ = 0.731, SE 0.072).
As for the single mpMRI sequences, T2WI showed excellent
agreement (Ƙ = 0.804, SE 0.065), while DCE and DWI
showed moderate (Ƙ = 0.554, SE 0.074) and good agreement
(Ƙ = 0.714, SE 0.058). Assessment of inter-reader agreement
is summarized in supplementary table 1.
Discussion
In this study, we retrospectively validated the accuracy of VI-
RADS in discriminating between NMIBC and MIBC in our
cohort of patients with BCa. Firstly, we found a low propor-
tion (5–10%) of false-negative exams, i.e., a small number of
MIBC in VI-RADS categories 1 and 2. As for the overall
performance of VI-RADS in differentiating NMIBC from
MIBC, we found an overall accuracy between 85% and 91%.
Table 3 Lesion characteristics
Characteristic Data
No. of lesions 103







median size1, median (IQR) 15 (12–26)












1 Lesion size is expressed inmmand it is calculated as thewidest diameter
of its surface abutting the bladder wall
2 The tumor location is described in accordance with the schematic map
of the bladder in supplementary fig. 3
Table 2 Patient demographics
Characteristic Data
No. of patients 75
Male (%) 62 (83)
Female (%) 13 (17)
Age, median (IQR) 69 (62–78)
Patients with previous NMIBC 28 (37)
Patients with NMIBC 53 (71)
Patients with MIBC 22 (29)







No. of patients who underwent RE-TURBT 58
No. of patients upstaged by RE-TURBT 5
No. of patients who underwent radical cystectomy 18
Eur Radiol
In the past decade, several authors have demonstrated the
ability of MRI to distinguish NMIBC from MIBC [15, 16].
The introduction of functional in addition to morphological
sequences has proved to be crucial in such distinction; partic-
ularly, DWI has been shown to be able to accurately T stage
BCa, thanks to the description of the Btumor stalk^ semiotics
by Takeuchi et al [17]. The utility of the stalk in describing T
stage was more recently confirmed by Wang et al [18]; our
results are in accordance with those authors, as we found that
81% of NMIBC presented with a stalk. Given the growing
interest in evaluating mpMRI performance in BCa local stag-
ing, three meta-analyses have recently addressed the issue,
finding a pooled sensitivity of 0.87 (95% CI 0.82–0.91),
0.92 (95% CI 0.88–0.95), and 0.90 (95% CI 0.83–0.94) and
specificity of 0.79 (95% CI 0.72–0.85), 0.87 (95% CI 0.78–
0.93), and 0.88 (95% CI 0.77–0.94), respectively [10, 11, 19].
In our study, sensitivity and specificity, though higher for
the more experienced reader 1, were in accordance with the
recent meta-analyses. Reader 1 obtained a sensitivity and
specificity of 91% and 89%, reader 2 had a sensitivity of
82% and a specificity of 85%. If the cutoff VI-RADS > 3
was used to define MIBC, the improvement in specificity
was minimal for both readers (89 to 94% and 85 to 89%,
respectively), with a significant decrease in sensitivity, espe-
cially for reader 2 (82 to 77%). Given the aggressiveness of
MIBC, we believe that it is of utmost importance to avoid
false-negative, and therefore, in our practice, we tend to con-
sider a VI-RADS category 3 tumor as MIBC until otherwise
proven. ROC curve analysis confirmed this finding, setting
the optimal criterion at VI-RADS > 2. Inter-reader agreement
analyzed by Cohen’s Ƙ was excellent for T2W imaging
(Ƙ = 0.804), moderate/good for the overall score and DWI
(Ƙ = 0.731 and 0.714 respectively), and only moderate for
DCE imaging (Ƙ = 0.554). We hypothesize that this discrep-
ancy could be attributed to the less widespread use of DCE in
clinical routine and therefore inter-reader agreement as for
DCE is likely to improve as mpMRI of the bladder becomes
more widespread.
Current approach to diagnosis and local staging of BCa has
several well-known limitations. To encourage further diffu-
sion of mpMRI into research and clinical practice, a panel of
experts recently proposed a 5-point scoring system aimed at
standardizing the use [12]. The VI-RADS scoring system,
however, is still in its infancy, and therefore it needs validation
against the available staging techniques.
Even if cystoscopy and TURBT are still considered the
gold standard, a substantial proportion of patients are
understaged at TURBT [20]. Moreover, TURBT frequently
needs to be repeated [6], but adherence to guidelines varies
between urologist [21]. Imaging modalities such as CT or
MRI are currently recommended by several guidelines for
Fig. 5 Comparison of receiver operating characteristics curve analysis for
both readers. AUC area under curve
Table 5 Sensitivity and
specificity of both readers for
each cutoff. In brackets, 95%
confidence interval
Reader 1 Reader 2
Sensitivity Specificity Sensitivity Specificity
VI-RADS > 1 100 (85–100) 11 (4–23) 100 (85–100) 0 (0–7)
VI-RADS > 2 91 (71–99) 89 (77–96) 82 (60–95) 85 (72–93)
VI-RADS > 3 82 (60–95) 94 (84–99) 77 (55–92) 89 (77–96)
VI-RADS > 4 36 (17–60) 98 (90–100) 36 (17–59) 98 (90–100)
VI-RADS > 5 0 (0–15) 100 (93–100) 0 (0–15) 100 (93–100)
Table 4 Proportion of muscle-invasive bladder cancer in each VI-
RADS category, for both readers
Reader 1 Reader 2
VI-RADS Patients (%) MIBC (%) Patients (%) MIBC (%)
1 6 (8) 0 8 (10) 0
2 43 (57) 2 (5) 41(55) 4 (10)
3 5 (7) 2 (40) 3 (4) 1 (33)
4 12 (16) 10 (83) 14 (19) 9 (64)
5 9 (12) 8 (89) 9 (12) 8 (89)
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local and distant staging, with the caveat that neither technique
can be accurate in differentiating T2 from higher-stage tumors
[5]. If a non-invasive diagnostic modality such as mpMRI was
considered reliable in identifying MIBC, the attending urolo-
gist could perform a Bdiagnostic^ TURBT and expedite radi-
cal treatment without waiting for patients to undergo a
TURBT and a RE-TURBT. On the other hand, if an NMIBC
could be identified preoperatively, the surgeon could be more
confident in performing a Bcurative^ TURBT.
This study has several limitations. Firstly, its retrospective
design carries a strong risk for selection bias, even though the
prevalence of MIBC in our cohort broadly reflects the epide-
miology of BCa [5]. In addition, it is a single-center study and
therefore all mpMRI were performed on the same highly
performing 3 Tmagnet, making the applicability of our results
to the clinical routine somewhat difficult. Nonetheless, BCa is
often treated at tertiary care center, and therefore the availabil-
ity of good equipment and expertise should not be of concern.
The need of multicentric validation studies is nonetheless
strong because radiologist working in the same reference cen-
ter could have very similar background, which reflects in the
way they interpret mpMRI exams. The lack of radical
cystectomy as a gold standard for all patients is another im-
portant limitation; however, for patients without a diagnosis of
MIBC, TURBT and RE-TURBT remain the best standard
available. Furthermore, we did not test the performance of
single sequences, and therefore we could not extrapolate any
information about a possible Bdominant sequence,^ as was
previously done for other scoring systems such as PI-RADS
[13]. In addition, we did not assess the accuracy of VI-RADS
by tumor location: some Bspecial^ locations such as the dome
and the trigone, may pose specific problems to the reader and
may need a more focused assessment, which is difficult to
standardize.
Another important limitation of the present study is the
restricted patient population offered mpMRI. Even though
the distinction between MIBC and NMIBC is imperative to
further direct patient management, the clinician may ask dif-
ferent question as regards to BCa. Particularly, van der Pol
et al showed that mpMRI can reliably stage BCa even after
TURBT [22]; however, their patient population consisted only
of patient with MIBC who underwent radical cystectomy. In
the setting of neoadjuvant therapy offered to patients with
MIBC, mpMRI is also uninvestigated; further studies will
clarify its role in this context, as suggested by Necchi et al
[23]. Finally, the accuracy of mpMRI in nodal staging was not
assessed in the present study, limiting its applicability as a
comprehensive staging tool. However, a recent meta-
analysis showed that MRI and PET/CT have a comparable
performance in nodal staging [24].
In conclusion, mpMRI with the use of VI-RADS is accurate
in differentiating MIBC from NMIBC and has a good sensitiv-
ity and specificity. Inter-reader agreement is overall good. Our
results support the use of mpMRI in patients with BCa before
TURBT, as it could give more confidence to the urologist in
performing a curative TURBT, or it could make him more
cautious in interpreting TURBT results. However, prospective,
multicentric studies are needed to validate the VI-RADS.
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